Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $846,215.37 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,295,854.56. This represents a 39.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Down 2.6%

Shares of Oruka Therapeutics stock traded down $2.23 on Monday, reaching $84.56. The company’s stock had a trading volume of 769,769 shares, compared to its average volume of 1,187,362. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of -43.59 and a beta of -0.35. The firm’s fifty day simple moving average is $70.54 and its two-hundred day simple moving average is $51.50. Oruka Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday. UBS Group boosted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings downgraded shares of Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Barclays lifted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $134.30.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ORKA. Royal Bank of Canada grew its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the period. Kennedy Capital Management LLC raised its position in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after acquiring an additional 420 shares during the period. AlphaCentric Advisors LLC raised its position in Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after acquiring an additional 626 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after acquiring an additional 788 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after acquiring an additional 904 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.